TY - JOUR
T1 - Insulin-like growth factor-1 preconditioning accentuates intrinsic survival mechanism in stem cells to resist ischemic injury by orchestrating protein kinase Cα-Erk1/2 activation
AU - Lu, Gang
AU - Ashraf, Muhammad
AU - Haider, Khawaja Husnain
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Aims: To test our hypothesis that the intrinsic molecular mechanism in stem cells for adaptation to ischemia is accentuated by preconditioning with insulin-like growth factor (IGF-1). Results: Bone marrow Sca-1 + cells were exposed to oxygen and glucose deprivation (OGD) for up to 12 h. Erk1/2 was activated in Sca-1 + cells under OGD which was blocked by MEK inhibitor (PD98059) and resulted in accelerated cell death. Moreover, elevated intracellular calcium with concomitant activation of protein kinase C (PKC) was observed under OGD. Pretreatment with nifedipine or dantrolene reduced cellular calcium, abrogated PKC and Erk1/2 activation, and increased cytotoxicity. Treatment with phorbol 12-myristate 13-acetate (PMA) for 30 min (short-term) activated Erk1/2, whereas 12 h (long-term) PMA treatment abrogated PKCα, reduced Erk1/2 activation and significantly increased cell death under OGD. These results were confirmed by loss-of-function studies using PKCα and Erk1/2 specific small interfering RNA. Gain-of-function studies with PKCα plasmid transfection improved cell survival under OGD. Preconditioning with 100 nM IGF-1 accentuated the intrinsic mechanism of resistance of the cells to ischemia via Erk1/2 activation and improved their survival under OGD as well as post-transplantation in an experimentally infarcted heart. Innovation: Strategies to target intrinsic survival mechanism in stem cells by growth factor preconditioning to enhance their survival via activation of PKCα and Erk1/2 are innovative. Conclusions: Intracellular calcium elevation under OGD activated PKCα and Erk1/2 as a part of the intrinsic prosurvival mechanism that was accentuated during preconditioning with IGF-1 to protect Sca-1 + cells from ischemic injury.
AB - Aims: To test our hypothesis that the intrinsic molecular mechanism in stem cells for adaptation to ischemia is accentuated by preconditioning with insulin-like growth factor (IGF-1). Results: Bone marrow Sca-1 + cells were exposed to oxygen and glucose deprivation (OGD) for up to 12 h. Erk1/2 was activated in Sca-1 + cells under OGD which was blocked by MEK inhibitor (PD98059) and resulted in accelerated cell death. Moreover, elevated intracellular calcium with concomitant activation of protein kinase C (PKC) was observed under OGD. Pretreatment with nifedipine or dantrolene reduced cellular calcium, abrogated PKC and Erk1/2 activation, and increased cytotoxicity. Treatment with phorbol 12-myristate 13-acetate (PMA) for 30 min (short-term) activated Erk1/2, whereas 12 h (long-term) PMA treatment abrogated PKCα, reduced Erk1/2 activation and significantly increased cell death under OGD. These results were confirmed by loss-of-function studies using PKCα and Erk1/2 specific small interfering RNA. Gain-of-function studies with PKCα plasmid transfection improved cell survival under OGD. Preconditioning with 100 nM IGF-1 accentuated the intrinsic mechanism of resistance of the cells to ischemia via Erk1/2 activation and improved their survival under OGD as well as post-transplantation in an experimentally infarcted heart. Innovation: Strategies to target intrinsic survival mechanism in stem cells by growth factor preconditioning to enhance their survival via activation of PKCα and Erk1/2 are innovative. Conclusions: Intracellular calcium elevation under OGD activated PKCα and Erk1/2 as a part of the intrinsic prosurvival mechanism that was accentuated during preconditioning with IGF-1 to protect Sca-1 + cells from ischemic injury.
UR - http://www.scopus.com/inward/record.url?scp=83255184378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83255184378&partnerID=8YFLogxK
U2 - 10.1089/ars.2011.4112
DO - 10.1089/ars.2011.4112
M3 - Article
C2 - 21923556
AN - SCOPUS:83255184378
SN - 1523-0864
VL - 16
SP - 217
EP - 228
JO - Antioxidants and Redox Signaling
JF - Antioxidants and Redox Signaling
IS - 3
ER -